Richard Davies Wins 'Best CEO in the Biomaterials Industry' Award From European CEO Magazine

LUND, Sweden, December 13, 2016 /PRNewswire/ --

BONESUPPORT AB, an emerging leader in innovative injectable bioceramic bone scaffolds to treat bone voids caused by trauma, infection, disease or related surgery, is pleased to announce that its CEO Richard Davies has won the "Best CEO in the Biomaterials Industry" award. The award was presented by European CEO Magazine based on Mr. Davies' track record at the forefront of major new healthcare trends and the continuing success of BONESUPPORT™ under his leadership.

Mr. Davies became CEO of BONESUPPORT in January 2016, following nearly four years spent at Hospira, where he served as Chief Commercial Officer. While at Hospira, he drove growth, globalization and modernization across the business. Hospira was acquired by Pfizer at the end of 2015. Prior to Hospira, Mr. Davies spent nine years in increasingly senior leadership positions at Amgen in Europe, Australia and the U.S. His roles included leadership of the U.S. Inflammation sales group, which commercialized Enbrel® (etanercept), the most prescribed biologic medicine in the U.S. at that time. Mr. Davies began his career at Eli Lilly, spending 13 years in increasingly senior positions.

Richard Davies, CEO of BONESUPPORT, said: "I am very humbled to have been given this award. I firmly believe that BONESUPPORT has an exciting future based on the significant potential of its unique CERAMENT™ platform. This platform is truly innovative and enables surgeons to improve patient outcomes across a range of orthopaedic indications, enabling a single stage surgical procedure for osteomyelitis, reduce length of stay in hospital and lower the cost of care. These benefits are based on the platform's important clinical features including its ability to rapidly remodel to host bone in six to 12 months, as well as being a carrier for therapeutics that enhance the bone healing process."

BONESUPPORT recently raised $37 million (SEK 327 million) to support the execution of its strategy to deliver significant shareholder value, focused on:

• Driving the sales of CERAMENT BONE VOID FILLER, CERAMENT G and CERAMENT V (with the antibiotics gentamicin and vancomycin respectively)
• Generating further clinical data to highlight the compelling benefits that the current CERAMENT products deliver
• Conduct the FORTIFY study to support a planned PMA filing in the US for CERAMENT G
• Building the Company's product pipeline by capitalizing on the unique drug-eluting properties of its injectable bioceramic platform

BONESUPPORT believes that the attractive properties of its CERAMENT platform will allow it to develop products that are both osteoconductive and osteoinductive for use managing a range of bone diseases where enhanced bone growth is needed to improve treatment outcomes.    

- Ends -

Notes to Editor 

About BONESUPPORT™  

BONESUPPORT has developed CERAMENT as an innovative range of radiopaque injectable osteoconductive bioceramic products that have a proven ability to heal defects by remodeling to host bone in six to 12 months. Our products are effective in treating patients with fractures and bone voids caused by trauma, infection, disease or related surgery. Our lead product, CERAMENT BONE VOID FILLER (BVF) addresses important issues facing health care providers, such as avoiding hospital readmissions and revision surgery that result from failed bone healing and infection caused by residual bone voids. CERAMENT BVF is commercially available in the U.S., EU, SE Asia and the Middle East.

CERAMENT's distinctive properties as a drug eluting material have been validated in clinical practice by CERAMENT G and CERAMENT V, the first CE-marked injectable antibiotic eluting bone graft substitutes. These products provide local sustained delivery of gentamicin and vancomycin, respectively. The local delivery feature enables an initial high concentration of antibiotics to the bone defect and then a longer sustainable dose above the minimal inhibitory concentration (MIC) to protect bone healing and promote bone remodeling.

CERAMENT G and CERAMENT V have demonstrated good results in patients with problematic bone infections including osteomyelitis. They are also used prophylactically in patients who are at risk for developing infection. CERAMENT G and CERAMENT V are available in the EU.

BONESUPPORT was founded in 1999 by Prof. Lars Lidgren, an internationally respected scientist who has been the President of various musculoskeletal societies. BONESUPPORT's mission is to bring people with bone and joint diseases back to an active life. The Company is based in Lund, Sweden. http://www.bonesupport.com

BONESUPPORT™ is a registered trademark. 

Contact Information

Citigate Dewe Rogerson
David Dible, Andrea Bici, Mark Swallow
+44 (0)20 7282 2949/1050/2948
bonesupport@citigatedr.co.uk